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Access to positron emission tomography (PET), and more recently PET combined with 
computed tomography (PET/CT), is increasing in veterinary medicine. This molecular 
imaging technology allows clinicians to map biological functions within patients based 
on the distribution and selective uptake of specialized positron-emitting 
radiopharmaceuticals. Although most clinical studies utilize 2-deoxy-2-[18F]fluoro-D-
glucose (18FDG), a versatile but relatively nonspecific tracer that interrogates the energy 
metabolism of tissues, there is a growing need to establish reference values for 
alternative or adjunct tracers in veterinary species. Among these is 3’-deoxy-3’-
[18F]fluorothymidine (18FLT), a thymidine analog that selectively accumulates in 
proliferating tissues. In the present work, 18FLT distribution in clinically healthy adult 
dogs and young adult cats was imaged using a state-of-the-art PET/CT scanner to 
define normal uptake levels within numerous tissues, including major parenchymal 
organs, bone marrow, and other sites of increased radiopharmaceutical uptake. The 
marrow signal was subsequently segmented into separate skeletal regions, and used to 
quantitatively define the adult marrow distribution pattern in the dog. Marrow activity is 
concentrated in the vertebral column (particularly within the thoracic and lumbar 
regions), sternum, ribs, and proximal aspects of the appendicular skeleton in the adult 
dog. Feline marrow distribution is similar; however, considerable uptake within more 
distal appendicular structures suggests that age-related marrow conversion is ongoing 
in 3-year-old cats. Outside the marrow compartment, physiologic uptake was observed 
within the urinary and biliary systems, intestinal tract, and variably within lymphoid 
structures. Prominent uptake within the hepatic parenchyma was also observed in cats, 
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but not dogs, at the times imaged in this study. The details of normal canine and feline 
18FLT biodistribution included in this dissertation may be used to inform lesion 
interpretation in dogs and cats with suspected disease. Likewise, quantitative details of 
adult marrow distribution in dogs may be used by clinicians to guide the selection of 
marrow sampling sites or inform tissue-sparing efforts during radiotherapeutic planning 
in canine patients.  
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Basic Historical and Technical Aspects of Positron Emission Tomography (PET) 
Functional imaging utilizing PET technology has played an increasingly important role in 
the management of human diseases in the past several decades [1-3]. Although the 
technology has existed since the 1960s [4], it was the late 1970s and 1980s when 
clinical interest began to develop around its use. Early reports predominately describe 
use in brain and cardiac disorders [4, 5]. At present, however, a PubMed search for 
“positron emission tomography” will yield over 70,000 results covering a broad range of 
applications ranging from psychiatry to oncology.  The breadth of possible applications 
relates to the core functional element of PET, the radiopharmaceutical.  
A PET radiopharmaceutical represents the coupling of two distinct functional 
components: a molecular vehicle that drives distribution within the patient and a 
positron-emitting radionuclide that allows that distribution to be detected, imaged, and 
quantified [6, 7]. The pharmaceutical vehicle may interact with a patient’s body through 
any of a variety of biologic processes in order to drive distribution of the tracer.  
Examples include cell surface interactions such as antigen–antibody coupling or 
receptor binding, acting as substrates for enzymes or transporters, or participating 
directly in metabolic processes [6]. Ultimately, selection of the pharmaceutical vehicle 
depends on the physiologic process that is being investigated. Although the 
radionuclide serves predominately as a label for detection, its selection must balance 
availability, practicality, and any potential impacts on the functional characteristics of the 
radiopharmaceutical. There are several positron-emitting radionuclides from which to 
choose (15O, 13N, 11C, 18F, 68Ga, and a few others); however, 18F is used most 
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commonly in the clinical setting due to its ability to be substituted into a number of 
biologically relevant molecules, manageable effects on biochemical characteristics, 
favorable imaging characteristics, and convenient half-life of 109.8 minutes [6, 7]. 
Detection and localization of tracer distribution is possible due to the unique physical 
properties of positron emission. When a positron-emitting radionuclide decays by 
transmutation of a proton to a neutron with the corresponding release of an electron 
neutrino, and more importantly, a positron (essentially a “positive electron”), that 
positron travels only a short distance before effectively running out of energy and 
annihilating with an electron from the surrounding tissue [7-9]. The distance traveled by 
the positron depends on the energy with which it is emitted, a characteristic of the 
particular isotope. For 18F (with an Emax of 633 keV), that range is around 0.6 mm on 
average [7]. The annihilation event results in the conversion of the masses of the two 
particles to a pair of characteristic 511 keV gamma rays, released almost exactly 180º 
apart. Ideally, these photons will strike opposing detectors of the PET camera in 
coincidence, allowing recovery of the location of the annihilation event along a line of 
response (LOR) connecting the detectors – a so-called “true” coincidence event. Each 
paired event is stored within the computer and used to reconstruct the distribution of the 
radioactivity using a reconstruction algorithm, thereby indirectly mapping the functional 
process being interrogated [2, 7-9].  
Historically, spatial resolution has been a limitation of PET with that of early scanners 
exceeding 15 mm [2]. In part, this is due to intrinsic limitations imposed by the physics 
of positron emission. Since LORs indicate the location of the annihilation event rather 
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than the actual position of the tracer, positron range inherently degrades spatial 
resolution. Moreover, if the kinetic energy carried by the positron is not entirely 
dissipated prior to annihilation, the resultant photons will be released at an angle less 
than 180º to conserve that momentum and the LOR assigned by the scanner will 
misrepresent their origin [7, 8]. While these effects impose a lower limit on achievable 
spatial resolution, there are a variety of other factors that can produce more substantial 
influences on image quality. True coincidences represent only a fraction of the total 
counts detected, and not all annihilation photons will even reach the detectors due to 
attenuation. Scatter, whereby photons interact with the tissue and are redirected prior to 
reaching the detectors (albeit at some energy less than 511 keV), and random 
coincidences, whereby 2 photons from unrelated annihilation events happen to strike 
apposing detectors within the coincidence time window, both contribute to background 
noise and degrade image quality [7]. Fortunately, improvements in detector design and 
materials (resulting in faster scintillation, reduced dead time, and improved energy 
resolution), electronics, and reconstruction algorithms have greatly improved image 
quality in modern clinical scanners with typical resolutions now in the 4-5 mm range [2, 
7, 10].  
Fusion of PET data with computed tomography (CT) has further enhanced clinical utility. 
While functional PET images generally offer little morphological information, CT can 
provide the high-resolution anatomical detail necessary to reliably localize variations in 
uptake [11, 12]. Beyond visual comparison of the two modalities by the reader, spatial 
co-registration of both datasets has been shown to further improve lesion localization 
accuracy [13]. Fusion was initially performed using software-based methods to align 
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scans produced by separate machines; however, time progression and movement 
between scans (particularly that of internal organs which cannot be eliminated) often 
complicated the process and success was limited beyond the brain [11]. More recently, 
combined PET/CT scanners, introduced in the late 1990s and early 2000s, have largely 
solved the alignment problem and expanded the utility of PET-CT fusion [3]. Inclusion of 
both modalities within a single housing has allowed the scans to be performed in 
immediate succession with no alterations to patient position. As such, this has produced 
more consistent co-registration and increased efficiency, as well as a convenient 
opportunity for improved attenuation correction [11].  
The degree to which tissues attenuate the signal from annihilation photons must be 
taken into account and corrections must be performed during image reconstruction to 
ensure the quantitative integrity of uptake data. Without attenuation correction, uptake is 
typically artifactually increased in the skin and lungs and non-uniform in other organs 
such as the liver and spleen. In order to calculate correction factors, stand-alone PET 
scanners require additional transmission scans with an external source of high energy 
photons (e.g. 68Ge rods). These scans extend overall imaging time and introduce 
additional noise into the data since the process relies on photon counting statistics [7]. 
Conversely, modern PET/CT scanners are able to make use of co-registered CT data to 
obtain the necessary correction factors. In this context, the patient’s CT scan, which can 
be performed in a fraction of the time needed to perform a separate PET-based 
transmission scan, provides what is essentially a map of attenuation coefficients at the 
mean CT x-ray energy (70-80 keV) [3, 7, 9, 12]. Although the data must be scaled to 
match the PET energy of 511 keV, CT-based correction is essentially noiseless and can 
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reduce scan times by more than 40% [3, 11, 12]. Accordingly, PET/CT continues to gain 
popularity and has become increasingly available at referral imaging facilities [2, 3, 14, 
15]. 
Current Status and Limitations of 2-Deoxy-2-[18F]Fluoro-D-Glucose (18FDG) 
At present, 18FDG is by far the most commonly used PET tracer in the clinical setting 
[6]. This 18F-labelled tracer is an analog of glucose that participates in the hexokinase 
reaction of glycolysis. The product of this reaction, 18FDG-6-PO4, is denied further 
metabolic progression due to the absence of a hydroxyl group at C-2 and becomes 
trapped within cells [16, 17]. The absence of a hydroxyl group at C-2 also prevents 
resorption in the renal tubule, increasing excretion of extracellular 18FDG and reducing 
background activity. As a result, imaging 18FDG distribution provides a map of tissue 
glycolytic activity with favorable signal-to-noise ratios for lesion detection in most tissues 
[17]. Human physiologic uptake normally occurs in metabolically active tissues 
(particularly the brain, but also skeletal muscles and myocardium under certain 
conditions, as well as variable uptake in lymphoid and gastrointestinal structures). Since 
18FDG is eliminated via the urine, intense uptake in the renal pelves, ureters, and 
urinary bladder is also a normal and prominent component of 18FDG distribution in 
humans [18-23]. Similar distribution is observed in common veterinary species [24-30]. 
Researchers have used 18FDG since the late 1970s [31] and it remains the first-line 
PET tracer for most clinical applications, including oncology, cardiology, and neurology 
[15, 32]. Since most pathologic conditions are accompanied by alterations in glucose 
management, 18FDG is especially versatile. Unfortunately, the nonspecific nature of 
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altered glucose metabolism can also represent a major drawback in certain situations 
[6]. Although 18FDG-PET is highly sensitive for detecting both primary and metastatic 
tumors due to their characteristic increased energy consumption, false-positive uptake 
is often also present in areas of infection or inflammation [23, 33, 34]. The utility of 
18FDG in measuring response to certain treatments, particularly those that often incite 
an inflammatory response, can be complicated [35, 36], and not all tumors are 18FDG 
avid [37, 38]. Moreover, physiologic uptake in metabolically active tissues can influence 
18FDG’s ability to discriminate lesions in these areas [18-20, 22, 23, 39]. While 18FDG 
will likely remain the workhorse of clinical PET for the foreseeable future, there is a 
need for validating alternative and adjunct imaging options for applications where a 
traditional 18FDG-PET scan is inadequate or inappropriate [40]. Direct measurement of 
proliferation frequently offers greater specificity than indirect measurement via energy 
metabolism. Consequently, radiopharmaceuticals that specifically target the pathways 
of DNA synthesis offer a useful alternative to characterize proliferative disorders [41]. 
3’-deoxy-3’-[18F]Fluorothymidine (18FLT) as a Proliferation Tracer 
18FLT, a close variant of the antiviral compound 3'-azido-3'-deoxythymidine (AZT), is the 
most prominent proliferation marker currently used in PET imaging [6, 42]. Both 
compounds are analogs of thymidine, the only nucleoside used in the production of 
DNA that is not also incorporated into RNA [43-45]. Structurally, 18FLT differs from 




18FLT uptake is facilitated by the pyrimidine salvage pathway, the mechanism by which 
thymidine and its analogs are transported into cells and phosphorylated as an initial 
step toward DNA synthesis [41]. Entrance into the cell is accomplished by both 
facilitated transport and passive diffusion [42], while phosphorylation occurs via 
thymidine kinase 1 (TK1) [43]. Phosphorylated 18FLT is trapped intracellularly, but 
lacking the necessary 3’-hydroxyl, never significantly incorporated into DNA [47]. 
Consequently, it is phosphorylation by TK1 that forms the basis of 18FLT accumulation 
rather than the entirety of DNA synthesis. This is very similar to the underlying 
mechanism of  18FDG, wherein phosphorylation by hexokinase rather than progression 
through the entirety of glucose metabolism is responsible for tracer retention [48]. 
Despite not being incorporated into DNA, there are several aspects of 18FLT metabolism 
that make it a suitable marker of proliferation. First and foremost, TK1 function is tightly 
regulated – activity is increased in proliferating and malignant cells but essentially 
absent in quiescent cells [49, 50]. Expression increases 10-fold during the synthetic 
phase of the cell cycle, but rapidly declines thereafter [49, 51]. Secondly, putative 
deoxynucleotidase-mediated dephosphorylation of 18FLT-monophosphate, the product 
of TK1, occurs slowly. Since the cell membrane is impermeable to phosphorylated 
18FLT, sluggish dephosphorylation limits efflux of the tracer and allows a stable retention 
window for imaging [52]. Finally, unlike thymidine, 18FLT is not degraded by thymidine 
phosphorylase (which would produce labeled metabolites) [52, 53], nor is it a substrate 
for thymidine kinase 2 (the isozyme involved in mitochondrial, rather than nuclear, DNA 
replication and repair) [54]. These factors simplify image analysis and link 18FLT 
exclusively to nuclear DNA synthesis [41]. 
9 
 
Oncologic imaging represents an obvious application for a tracer that measures cellular 
proliferation. 18FLT uptake has been shown to correlate strongly with traditional 
measures of proliferation, including Ki-67 immunostaining, for a variety of human 
cancers [41, 47, 55]. Unfortunately, however, there are a number of factors that can 
influence 18FLT uptake. It is important to consider the cell population that is being 
interrogated when evaluating suitability. Since it is the salvage pathway that governs 
retention of the tracer, factors that influence the utilization of this pathway, such as the 
existing cellular thymidine concentration or predilection toward the de novo pathway, will 
impact imaging performance [56, 57]. Likewise, recent administration of certain 
chemotherapeutic agents that cause upregulation of the salvage pathway, like 5-
fluorouracil or methotrexate, may confound interpretation [58]. 18FLT-based imaging 
often displays lower uptake levels and/or sensitivity when compared to 18FDG for 
detecting most cancers [47, 59-66]; however, greater specificity in many applications, 
particularly when inflammation or lymph node involvement may be implicated, supports 
that there is a role for 18FLT in cancer imaging [62-67]. While it is unlikely that 18FLT will 
replace 18FDG for most initial tumor detection or staging efforts, a number of recent 
studies have demonstrated promising results for the use of 18FLT in evaluating 
treatment response or predicting relapse [68-73]. 
Physiologic Distribution and Metabolism of 18FLT 
Human studies have primarily demonstrated physiologic 18FLT uptake in the bone 
marrow, liver, kidneys, and urinary bladder. Bone marrow is a known site of abundant 
proliferation related to blood cell production. The other organs are primarily involved in 
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metabolism or excretion of the tracer. Unlike 18FDG, little to no uptake is seen in the 
brain, myocardium, or skeletal muscle [47, 74]. Preclinical work in the canine exhibited 
similar qualitative biodistribution to the human, although hepatic parenchymal uptake 
was reduced and uptake was also noted in the mandibular lymph nodes and muzzle 
[43]. Lymph node aspirates were not collected, but the observed lymphoid uptake may 
have been due to reactive B-lymphocyte proliferation within germinal centers [75].  
Metabolism within the liver occurs via glucuronidation, the process by which glucuronic 
acid is transferred to chemical compounds to form metabolites that are more hydrophilic 
and readily excreted [76]. Glucuronidation is facilitated by a group of conjugative 
enzymes known as UDP-glucuronosyltransferases (UGTs) which originally evolved to 
detoxify various chemicals found in dietary plants but are now important contributors to 
drug metabolism [77]. The specific isozyme responsible for AZT glucuronidation in 
humans is UGT2B7 [78]; therefore, it is likely that this isozyme also facilitates 18FLT 
metabolism. In the human, this process is an important contributor to 18FLT kinetics, 
with approximately 25% of the plasma activity present as 18FLT-glucuronide at 60 
minutes post-injection [76]. Conversely, analyses of canine blood and urine suggest that 
the glucuronide pathway contributes very little to 18FLT elimination in the dog and that 
the vast majority of 18FLT is excreted unchanged [43, 79, 80]. These findings likely 
explain the disparity observed in hepatic uptake between the two species, and are 
consistent with the in vitro metabolism of AZT by cultured hepatocytes. This suggests 
glucuronidation is far more active in the livers of humans than of dogs [81].  
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Unfortunately, there appear to be no data available concerning the metabolic fate of 
18FLT or AZT in cats; however, multiple UGTs, including UGT2B7, are known to be 
minimally expressed or absent in the feline liver [82]. As obligate carnivores, cats likely 
had little need for these enzymes during their evolution, but their absence now impacts 
the metabolism of several pharmaceutical agents. Most notably, the prolonged 
clearance and remarkable sensitivity to the adverse effects of certain nonsteroidal anti-
inflammatory drugs in cats is attributed to diminished glucuronidation capacity [77, 83]. 
It is not clear whether alternative metabolic pathways exist in cats which may impact 
metabolism of 18FLT.  
Bone Marrow Assessment Using 18FLT 
As a prominent feature of physiologic distribution, 18FLT uptake in bone marrow has 
been comprehensively defined in humans [47, 74, 84]. Kinetic evaluation shows rapid 
early accumulation and persistent high retention of 18FLT in proliferating marrow. In part, 
this is because the salvage pathway is particularly robust in the marrow related to the 
recovery of DNA lost during red blood cell enucleation [85]. As a non-invasive, whole-
body means to quantitatively evaluate hematopoietic marrow, 18FLT has garnered 
attention in human medicine not only for its ability to delineate normal active marrow 
sites to maximize tissue sparing during external beam radiation planning [84, 86, 87], 
but also for characterizing hematopoietic disorders [88-90]. Several studies have 
likewise utilized 18FLT to illustrate the exquisite sensitivity of cycling bone marrow to 
radiation insult [91-94]. Irradiation of the marrow with as little as 2 Gy has been shown 
to visibly reduce uptake of the tracer, presumably due to cell cycle arrest, while a 
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fractionated dose of 10 Gy appears to have been sufficient to cause hematopoietic cell 
death within the radiation field [92]. 
Similar applications are logical and worthwhile in veterinary species. In particular, with 
growing veterinary access to advanced tissue-sparing radiotherapy techniques [95], 
comprehensive, species-specific descriptions of active marrow distribution will be 
increasingly relevant to veterinary clinicians concerned about inducing hematologic 
toxicity. 
18FLT-PET in Veterinary Medicine 
Access to PET and PET/CT remains relatively limited in veterinary medicine, although 
usage in academic settings is gaining traction. In part, this is due to growing recognition 
that the use of advanced techniques in animals can improve not only animal health, but 
also that of humans through research collaborations between physicians and 
veterinarians [67].  
Similar to human medicine, most veterinary PET imaging is performed with 18FDG [15]; 
however, a number of investigators have begun using 18FLT in recent years to image a 
variety of canine cancers including bronchoalveolar carcinoma [96], lymphoma [70], 
fibrosarcoma [97], and various sinonasal tumors [80, 98-102]. Many of these studies 
have focused on the utility of 18FLT for measuring or predicting response to therapy with 
favorable results [70, 96, 97, 100, 102].   
Despite growing veterinary interest, quantitative details of normal 18FLT biodistribution in 
veterinary species remain limited in the literature [1]. Comprehensive knowledge of 
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normal distribution and relative uptake levels within a given species is an integral 
component of image interpretation as readers must be able to reliably discriminate 
abnormal from normal uptake within tissues [103]. Although the dog was used as a 
model during early in vivo evaluations of 18FLT [43, 79], these descriptions offer few 
quantitative details for evaluation, not all areas of uptake visible in the included images 
are discussed, and image quality is considerably lower than what is possible today with 
modern PET/CT. 
Quantifying Uptake in PET Images 
Each voxel within a PET image represents the activity concentration (Bq/ml) within that 
volume. As a result, PET images are inherently quantitative [104]. Although clinical 
interpretation is often based principally on visual assessment [1], quantitative analysis 
can augment this process, and when scans are acquired and analyzed under 
standardized conditions permit more objective comparisons to be made between 
studies [104]. 
In basic terms, there are generally two approaches for quantifying uptake in PET 
studies – kinetic analysis and static analysis. Since kinetic approaches require dynamic 
imaging to be performed, which limits the field of study to a single bed position per scan, 
most clinical PET studies rely on the calculation of standardized uptake values (SUVs) 
from static images [104]. SUVs represent a “semi-quantitative” approach to analysis 
which normalizes activity within a region of interest (ROI) based on the dose injected 
and the size of the patient [105]. SUVs are most commonly calculated based on body 
weight (i.e. SUV = tissue concentration (Bq/ml) / (injected dose [Bq] / body weight [g]), 
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but lean body mass or body surface area may also be used. A value of 1.0 suggests 
that there is no meaningful concentration of the tracer by a given tissue, while values 
greater than 1.0 indicate that some mechanism of concentration is occurring [106]. SUV 
calculations may be based on maximum, minimum, or average tissue concentrations, 
but maximum values are most commonly used in lesion analysis [15]. 
Despite their popularity, SUVs have been criticized because they are subject to 
variability from a number of sources, including several patient-, protocol-, and 
equipment-related elements [107]. Among these elements are factors such as patient 
body condition, competing transport effects (e.g. competition for glucose transporters 
with elevated circulating glucose concentrations in the case of 18FDG), dose 
administered, length of uptake period, ROI size and designation parameters, 
reconstruction method, and equipment capabilities [104, 107-109]. Nevertheless, kinetic 
approaches suffer from many (though not all) of the same influences, and SUVs are 
considered to be similarly discriminating diagnostically [105]. Regardless of method, 
comparisons between institutions require careful consideration of all image acquisition 
and analysis factors and should be approached cautiously. Although comparisons 
between institutions should be approached cautiously, SUVs calculated with strict 
adherence to data acquisition and analysis protocols can be a fairly reliable and 
reproducible measure of tissue uptake [104]. Accordingly, most quantitative descriptions 
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Abstract 
Positron emission tomography/computed tomography (PET/CT) utilizing 3'-deoxy-3'-
[18F]fluorothymidine (18FLT), a proliferation tracer, has been found to be a useful tool for 
characterizing neoplastic diseases and bone marrow function in humans. As PET and 
PET/CT imaging become increasingly available in veterinary medicine, knowledge of 
radiopharmaceutical biodistribution in veterinary species is needed for lesion 
interpretation in the clinical setting. The purpose of this study is to describe the normal 
biodistribution of 18FLT in adult domestic cats. Imaging of six healthy adult castrated 
male cats was performed using a commercially available PET/CT scanner consisting of 
a 64-slice helical CT scanner with an integrated whole-body, high-resolution LSO PET 
scanner. Cats were sedated and injected intravenously with 108.60 ± 2.09 (mean±SD) 
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MBq of 18FLT (greater than 99% radiochemical purity by HPLC). Imaging was 
performed in sternal recumbency under general anesthesia. Static images utilizing 
multiple bed positions were acquired 80.83 ± 7.52 (mean±SD) minutes post-injection. 
Regions of interest (ROIs) were manually drawn over major parenchymal organs and 
selected areas of bone marrow and increased tracer uptake. Standardized Uptake 
Values (SUVs) were calculated. Notable areas of uptake included hematopoietic bone 
marrow, intestinal tract, and the urinary and hepatobiliary systems. No appreciable 
uptake was observed within brain, lung, myocardium, spleen, or skeletal muscle. 
Findings from this study can be used as baseline data for future studies of diseases in 
cats. 
Introduction 
Positron emission tomography (PET) is a functional imaging modality widely used in 
human medicine for the diagnosis and management of neoplastic and nonneoplastic 
diseases [1]. More recently, the fusion of functional PET data (which is generally 
characterized by relatively low spatial resolution) with high-resolution morphologic data 
from computed tomography (CT) has resulted in a powerful diagnostic tool capable of 
precise anatomic localization of radiopharmaceutical uptake [2]. With PET and PET/CT 
becoming increasingly available to veterinary researchers and clinicians, knowledge of 
the normal biodistribution of popular radiopharmaceuticals in veterinary species is 
needed in order to reliably discriminate normal from abnormal uptake. 
At present, 2-deoxy-2-[18F]fluoro-D-glucose (18FDG), a metabolic tracer which 
interrogates the glucose metabolism of tissues, remains the most commonly used PET 
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tracer in the clinical setting, regardless of species [3-5]. Although 18FDG will likely 
remain the workhorse of clinical PET for the foreseeable future, the nonspecific nature 
of increased glucose consumption as an indicator of disease can make it difficult in 
some situations to discriminate malignancy from inflammation or to identify 18FDG avid 
lesions within metabolically active normal tissues like the brain [6, 7].  
Radiopharmaceuticals that specifically target the pathways of DNA synthesis offer a 
useful alternative to aid in the characterization of proliferative disorders [8]. 3’-deoxy-3’-
[18F]fluorothymidine (18FLT) is the most prominent proliferation marker currently used in 
PET imaging [3, 9]. As a thymidine analog, 18FLT participates directly in the salvage 
pathway of DNA synthesis as a substrate for thymidine kinase 1 (TK1) [9, 10]. 
Phosphorylation by TK1 results in 18FLT becoming trapped within cells and forms the 
basis of 18FLT-PET imaging. Although 18FLT is not significantly incorporated into DNA 
due to the absence of a 3’-hydroxyl moiety, TK1 activity is tightly regulated throughout 
the cell cycle and most reports have demonstrated correlation between 18FLT uptake 
and more traditional measures of proliferation, including Ki-67 scores [8, 10].  
Numerous studies in humans have demonstrated the utility of 18FLT in the diagnosis, 
staging, measurement of therapeutic response, and prediction of outcome in a variety of 
malignancies [8]. 18FLT-PET has also been used to characterize proliferative bone 
marrow in relation to therapeutic planning [11, 12], response to insult [13-15], and 
hematologic disease [16-18]. Underscoring the potential for translation of this tracer into 
veterinary applications, early preclinical studies included normal and diseased dogs and 
two reports within the veterinary literature document the successful use of 18FLT in dogs 
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to characterize neoplastic disease and assess therapeutic response [9, 19-21]. To date, 
however, there have been no reports detailing 18FLT uptake or use in cats. The purpose 
of this study was to describe 18FLT uptake in normal adult cats to facilitate use of 18FLT-
PET for future clinical applications in this species. 
Methods 
Six healthy adult cats were acquired from a dedicated research colony maintained 
through the laboratory animal facilities at the University of Tennessee. All cats were 
purpose-bred domestic short hair castrated males, 3 years of age, and weighed 5.59 ± 
0.73 kg (mean ± SD; range 4.77 – 6.41 kg).  Animals were housed in Institutional 
Animal Care and Use Committee (IACUC)-approved facilities throughout the study and 
all procedures were conducted in accordance with a University of Tennessee IACUC-
approved protocol.  Subjects were deemed healthy based on results of physical 
examination, recent hematology and clinical chemistry testing, and routine clinical 
history as university-housed research animals. In addition, no abnormalities were noted 
in any animal upon evaluation of whole-body computed tomography (CT) during the 
study. 
18FLT was synthesized through the radiopharmaceutical facilities at the University of 
Tennessee Graduate School of Medicine using a flow-based microfluidic chemistry 
system. The resultant microreactor product was purified by semi-prep high-performance 
liquid chromatography (HPLC) resulting in >99% radiochemically pure 18FLT for 
injection. All doses were verified to be free of endotoxin prior to injection. 
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All animals were fasted for a minimum of 12 hours prior to general anesthesia for 
imaging. Following intravenous catheter placement, subjects were sedated with 
acepromazine (0.025-0.05 mg/kg) and butorphanol (0.2-0.4 mg/kg) and injected 
intravenously with 108.60 ± 2.09 MBq 18FLT (mean ± SD). Animals were subsequently 
confined to a small cage for approximately 1 hour in order to allow distribution and 
tissue uptake of the radiopharmaceutical. Animals were then transferred to the scanner 
bed where general anesthesia was induced via intravenous bolus of propofol (titrated to 
effect; ≤ 4 mg/kg), followed by endotracheal intubation and anesthetic maintenance with 
inhaled isoflurane.  
All cats were imaged in sternal recumbency using the same PET/CT scanner (Biograph 
mCT, Siemens Medical Solutions USA, Inc., Knoxville, TN ).  This scanner combines a 
64-slice helical CT scanner with a high-resolution lutetium oxy-orthosilicate (LSO) PET 
scanner. The scanner incorporates a 50 cm transverse (x-y axes) by 21.8 cm (z axis) 
diagnostic field-of-view within the 78 cm patient bore. Whole-body, static PET/CT 
images were acquired 80.83 ± 7.52 (mean±SD) minutes after 18FLT injection.   
Following an initial topogram to define the area of interest, a CT scan was performed for 
attenuation correction as well as to aid in image analysis. Computed tomography scans 
were performed at 120 kV and 150 mAs, using the scanner’s automated radiation dose 
reduction protocol (Care Dose™, Siemens Medical Solutions USA, Inc., Knoxville, TN) 
and using a 0.8 pitch and a 0.6 mm slice width. Computed tomography data were 
reconstructed using 5 mm and 2.5 mm slice thicknesses. Immediately following CT 
acquisition, a whole-body PET scan was performed with no alteration in subject 
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positioning. Five to 7 bed positions were necessary to encompass the entire body of the 
cats. Positron emission tomography data were acquired for 3 minutes per bed position 
with an energy window setting of 435-650 keV. Positron emission tomography data 
were reconstructed using the scanner’s specific iterative reconstruction algorithm 
(TrueX algorithm, Siemens Medical Solutions USA, Inc., Knoxville, TN) with 3 iterations 
and 12 subsets, resulting in a reconstructed pixel size of 4.07 mm x 4.07 mm. Data 
were normalized and corrected for dead time, attenuation, scatter, and radioactive 
decay.  
Regions of interest (ROIs) were manually drawn by a veterinarian trained in ROI 
placement and molecular image analysis over sites of clinical relevance and areas of 
increased tracer uptake, including major parenchymal organs and selected areas of 
bone marrow (Figure 1.1A-D) using dedicated analysis software (Inveon Research 
Workplace v3.0, Siemens Medical Solutions USA, Inc., Knoxville, TN). Most ROIs were 
drawn using transverse plane images; however, dorsal plane images were used for 
liver, renal cortices, spleen, intestine, and myocardium. Renal cortical ROIs were 
carefully drawn such that the renal pelvis was excluded as intense activity within the 
renal collecting system is associated with urinary excretion of the tracer. Large, 
homogeneous volumes of tissue (liver, lung, and epaxial muscle) were assessed via 
placement of single, spherical volumetric ROIs in a representative area.  Care was 
taken to avoid inclusion of large airways within the lung. Standardized uptake values 
(SUVs) based on the mean and maximum voxel intensity values within each ROI were 
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All calculations were decay-corrected to injection time. The resultant 18FLT-SUVs were 
categorized based on the following definitions: (1) low = maximum SUV less than 1; (2) 
mild = maximum SUV greater than 1 but less than 2.5; (3) moderate = maximum SUV 
greater than 2.5 but less than 5; (4) intense = maximum SUV 5 or greater. 
Results 
Mean and maximum SUVs for selected ROIs are summarized in Table 1.1. The mean 
SUV was not assessed for intestinal uptake due to the irregular uptake patterns. Whole-
body images illustrating biodistribution patterns are provided in Figure 1.2A and B. 
The greatest regional uptake values occurred in the urinary and hepatobiliary systems. 
Variable mild to moderate intestinal 18FLT uptake was observed and included numerous 
focal areas of increased uptake, predominately within the small intestine.  However, 
occasional foci of increased uptake were observed within the large intestine. It was not 
possible to identify a specific portion of the intestine to draw a repeatable ROI because 
the uptake was variably diffuse to multifocal.  Therefore quantitative evaluation of 
intestinal uptake was limited to calculation of a maximum SUV, and this was assessed 
using a single dorsal plane ROI encompassing the majority of the small intestine. It was 
also not possible to determine whether the intestinal uptake was due to tracer 
accumulation within the intestinal wall, lumen, or some combination thereof.  
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Considerable tracer uptake within the bone marrow was observed, ranging from mild to 
moderate intensity (Figure 1.3A and B). The highest tracer uptake within the marrow 
compartment was primarily associated with the vertebral column, sternum, and proximal 
appendicular skeleton. Uptake within the distal aspect of the femur was also observed 
and was consistently among the highest intensity regions within the bone marrow. Focal 
marrow uptake was also observed within the regions of the external occipital 
protuberance, humeral condyles, and mandibular condyles in some animals. Although 
vertebral marrow uptake was assessed within the vertebral bodies of C6, T5, L4, and 
the sacrum; tracer activity was present throughout the vertebral column (excluding the 
caudal vertebrae). 
Tracer uptake within the brain, lung, myocardium, and skeletal muscle was low. Splenic 
uptake was mild (maximum SUV of 1.18, mean SUV below 1).  
Discussion 
Physiologic uptake of 18FLT in the cats of this study appeared to be greatest in the 
hematopoietic bone marrow, intestine, and the hepatobiliary and urinary systems. 
Observed uptake in these regions for normal cats should therefore be taken into 
consideration for future clinical applications in cats with suspected disease. Minimal 
uptake in the normal brain, lung, myocardium, skeletal muscle, and spleen should also 
be taken into consideration for future clinical studies.  These general patterns were 
consistent with normal uptake in other species that have been previously described.  
Intense activity within the urinary system was most likely due to elimination of the tracer 
via the kidneys. Moderate uptake within the hepatic parenchyma and intense activity 
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within the gallbladder was unexpected and may have been caused by hepatic 
metabolism and biliary excretion of 18FLT. The pattern of uptake in the bone marrow 
was expected, given that hematopoietic bone marrow is a well-known site of rapid 
cellular proliferation. The salvage pathway is particularly active in marrow due to the 
reclamation of DNA resulting from abundant red blood cell enucleation [23]. As 
expected in an adult animal, marrow activity in our cats was predominantly concentrated 
within the axial and proximal appendicular skeleton [24]. Indeed, the highest marrow 
SUV measurements in this study were observed within the proximal aspect of the 
humerus (maximum SUV = 4.85), a common site for bone marrow sample collection in 
veterinary species.  Iliac uptake was also observed.   However, measurements were 
higher in the caudal aspect of the body of the ilium (immediately cranial to the 
acetabulum) than in the wing of the ilium (maximum SUVs of 3.03 and 1.86, 
respectively). Interestingly, the distal femoral epiphyses had among the highest marrow 
uptake measurements in this study (maximum SUV = 3.80). This is in contrast to the 
established distribution of 18FLT in humans where adult appendicular marrow uptake is 
limited to the ultraproximal extremity bones [16].  
All cats in this study were 3 years of age, thus no assessment of age-related marrow 
conversion could be determined. Distribution of hematopoietic marrow varies as a 
function of age. Although active marrow is found throughout the skeleton of newborn 
mammals, it is progressively replaced by yellow or fatty marrow as the animal matures 
[24]. Previous studies in dogs and humans have used magnetic resonance imaging 
(MRI) to describe bone marrow composition. This technique has been used to describe 
lumbar vertebral, pelvic, and femoral marrow characteristics in the adult canine as well 
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as age-related marrow conversion in the canine pelvis, femur, and stifle joint [25-27]; 
however, no such data are available in cats. A report using T1-weighted magnetic 
resonance imaging has evaluated age-related marrow conversion in the human 
mandible. Human mandibular bone marrow conversion progresses caudally with the 
condyle representing the final remaining region of active hematopoietic marrow and it 
too disappears in adolescence [28]. Three of six cats in this study had observable tracer 
uptake within the mandible, each limited to a focal area within the condyle. This 
suggests that marrow conversion may still be taking place in 3-year-old cats. It is 
unknown what effects age-dependent conversions would have on the increased tracer 
uptake observed within the distal femora and variable uptake noted within the distal 
humeri. Future studies are needed in cats of varying ages, particularly older animals, in 
order to define differences in marrow SUVs that may be attributable to patient age. 
Intestinal 18FLT uptake was present in all 6 cats although uptake pattern was irregular 
and was typified by focal areas of increased tracer accumulation throughout the 
intestine. Despite CT fusion, it was not clear whether the uptake was related to the 
intestinal wall, lumen, or a combination of both sites. The addition of both intravenous 
and oral contrast media administration to the CT imaging protocol may have enabled 
this discrimination. Intestinal mucosa is a rapidly proliferative tissue and this most likely 
explains some component of the intestinal uptake of 18FLT we observed in our cats. 
This is further supported by uptake present throughout the intestine, with scans 
performed on fasted animals ≤92 minutes from tracer injection.  
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In addition to intense uptake within the gallbladder, moderate hepatic tracer uptake was 
observed in all cats in this study (maximum SUV = 4.00). Previous reports concerning 
the metabolic fate of 18FLT and/or the related compound 3’-azido-3’-deoxythymidine 
(AZT) have indicated that hepatic metabolism via glucuronidation occurs to a variable 
extent depending upon species [29]. Glucuronidation is the process by which glucuronic 
acid is transferred to chemical compounds resulting in metabolites that are more 
hydrophilic and readily excreted [30]. Strong hepatic uptake has been described as 
characteristic of human 18FLT biodistribution while canine hepatic uptake has been 
found to be considerably less by comparison [9]. This relationship is consistent with 
kinetic studies in each species which demonstrate that, while circulating 18FLT remains 
mostly unchanged in the dog, 18FLT-glucuronide represents approximately one-fourth of 
the measured blood activity at 60 minutes in humans [19, 23]. Aside from 
phosphorylation by TK1 in the salvage pathway, glucuronidation is the only documented 
major metabolic consequence of 18FLT [23].  
Following this logic, hepatic uptake in the domestic cat would be expected to be very 
low. As an obligate carnivore, cats lack certain UDP-glucuronosyltransferases (UGTs), 
the group of hepatic enzymes responsible for facilitating glucuronidation, due to genetic 
mutations found throughout felidae. While these enzymes are mainly discussed in the 
context of synthetic drug metabolism, they likely evolved in large part to detoxify dietary 
chemicals encountered in plant-based diets. Since cats consume a diet composed 
primarily of animal matter, these evolutionary selective pressures could be altered, 
allowing genes which control these enzymes to become dysfunctional [30]. Diminished 
glucuronidation abilities are considered responsible for the prolonged clearance and 
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remarkable sensitivity of cats to the adverse effects of certain non-steroidal anti-
inflammatory drugs [31]. Our finding of relatively high hepatic tracer uptake in the face 
of the poor glucuronidation capacity characteristic of cats may indicate that alternative 
metabolic pathways are responsible for hepatic uptake in this species. Further studies in 
a larger number of cats are needed to define the nature of the hepatobiliary 18FLT 
uptake, and to characterize the metabolic fate of 18FLT in this species.   The presence 
of possible circulating metabolites may impact image analysis for future clinical patients.  
Measurements of regional tracer uptake in this study were expressed using SUV.  This 
is a semiquantitative measure derived from static images that normalizes activity within 
a ROI for the specific radiopharmaceutical dose administered and the individual 
patient’s body weight. This measure is commonly used clinically because it allows 
multiple bed positions to be assessed simultaneously from a single PET scan performed 
at a fixed time post-injection [22, 32-34]. Despite widespread usage, the SUV has been 
scrutinized as it can be influenced by several patient, scanner, and protocol-related 
factors. Some important sources of variability include patient body composition, lesion 
size and location, equipment specifications, duration of uptake period, choice of 
reconstruction algorithm, and ROI designation parameters [22, 35-37]. As a result, strict 
standardization and protocol adherence is necessary to achieve repeatability and 
caution must be exercised when comparing SUV data between institutions and species 
[35, 38].  
As veterinary clinicians and researchers continue to gain access to PET technology, 
availability of baseline biodistribution data in veterinary species will be critical. To the 
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authors’ knowledge, this is the first report of 18FLT imaging in the cat. This study 
describes the physiologic uptake pattern of 18FLT in a small cohort of healthy young 
cats and can be used as a baseline for future clinical application and interpretation of 
18FLT-based imaging in this species. 18FLT-PET and 18FLT-PET/CT have already been 
used successfully in humans to diagnose, characterize, and manage a variety of 
neoplasms and hematopoietic disorders [8, 10-18]. Moreover, veterinary reports 
involving naturally occurring canine lymphoma, sarcoma, and bronchoalveolar 
carcinoma have demonstrated the utility of 18FLT in detecting neoplastic lesions, 
evaluating therapeutic response, and recognizing disease recrudescence in dogs; the 
latter case report highlighting 18FLT’s usefulness as an adjunct to 18FDG in the 
presumptive discrimination of inflammation from proliferative tumor [9, 20, 21]. Potential 
applications and indications for this imaging modality in the cat should mirror those 
described in other species with obvious relevance to the field of oncology and 
assessment of bone marrow proliferation. Physiologic uptake within the liver, bone 
marrow, urinary system, and variable uptake within the intestine may complicate 
detection of lesions within these tissues due to background uptake levels. Further 
studies are needed to describe 18FLT uptake patterns in healthy cats of varying ages, 
determine how 18FLT metabolism occurs in cats, and describe 18FLT-PET/CT 
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Table 1.1 Mean and maximum standardized uptake values of 18FLT uptake measured 
with positron emission tomography/computed tomography for selected regions in 













Urinary Bladder 157.55 (55.73) 220.38 (69.14) 
Gallbladder 9.62 (2.46) 11.29 (3.12) 
Renal Cortex 4.33 (0.80) 6.14 (1.43) 
Proximal Humerus 3.70 (0.95) 4.85 (1.39) 
Liver 3.75 (0.38) 4.00 (0.44) 
Distal Femur 2.79 (0.76) 3.80 (1.11) 
Intestine ― 3.52 (0.71) 
L4 Vertebral Body 2.50 (0.71) 3.17 (0.98) 
Body of Ilium 2.73 (0.84) 3.03 (0.96) 
Sacrum 2.33 (0.63) 2.94 (0.77) 
Sternum 2.27 (0.69) 2.44 (0.78) 
T5 Vertebral Body 1.98 (0.46) 2.24 (0.41) 
Proximal Femur 1.78 (0.64) 2.01 (0.76) 
Wing of Ilium 1.72 (0.31) 1.86 (0.48) 
C6 Vertebral Body 1.57 (0.45) 1.75 (0.51) 
Spleen 0.93 (0.13) 1.18 (0.15) 
Epaxial Muscle 0.91 (0.10) 0.96 (0.11) 
Myocardium 0.79 (0.10) 0.84 (0.12) 
Brain 0.25 (0.06) 0.47 (0.10) 
Lung 0.25 (0.04) 0.28 (0.05) 
    
  




SUV, standardized uptake value; SD, standard deviation.  
SUV’s for all paired structure regions of interest were calculated by summing data for both left 
and right sides. Measurements were made 80.83 ± 7.52 (mean±SD) minutes after injection. All 





Figure 1.1 Fused positron emission tomography/computed tomography (PET/CT) 
images depicting how regions of interest (ROIs) were drawn for cats. (A) ROIs outlining 
the left (purple) and right (yellow) renal cortices were drawn to exclude the renal 
pelvises (asterisks) on dorsal plane images. A portion of the spherical liver ROI is 
outlined in red. (B) Large dorsal plane ROI outlining the small intestinal tract (green). (C) 
Transverse plane images were used to outline the 4th lumbar vertebral body (light blue). 
(D) Transverse plane ROI outlining uptake within the distal femoral epiphysis (blue).  




Figure 1.2 Representative images illustrating 18FLT whole-body biodistribution patterns 
observed in healthy young adult cats at 80.83 ± 7.52 (mean±SD) minutes post-injection. 
Dorsal (A) and sagittal (B) plane positron emission tomography maximum intensity 
projections are provided. Each dorsal plane image corresponds to the sagittal plane 








Figure 1.3 Oblique 3-dimensional fused positron emission tomography/computed 
tomography images highlighting 18FLT uptake within feline hematopoietic bone marrow. 
(A) Note strong uptake within the proximal aspects of the humeri, a common marrow 
sampling site in the cat. Uptake is also visible within the cervical and thoracic vertebral 
bodies and sternum (B) Note strong uptake within the caudal aspects of the bodies of 
the ilia and the distal aspects of both femora. Uptake is also present within lumbar and 











WHOLE-BODY BIODISTRIBUTION OF 3'-DEOXY-3'-[18F]FLUOROTHYMIDINE 
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Abstract 
Positron emission tomography/computed tomography (PET/CT) utilizing 3’-deoxy-3’-
[18F]fluorthymidine (18FLT), a marker of cellular proliferation, is increasingly recognized 
as a useful tool in the characterization of various cancers and bone marrow function. 
Although use of this technology in veterinary medicine has been limited, access to and 
interest in PET and PET/CT is increasing. Accordingly, detailed knowledge of the 
biodistribution of relevant tracers in veterinary species is required to properly interpret 
studies in the clinical setting. The purpose of this study is to describe the normal 
biodistribution of 18FLT in dogs. Six healthy, adult, mixed-breed dogs were imaged 
utilizing a commercially available PET/CT scanner consisting of a 64-slice helical CT 
scanner combined with an integrated whole-body, high-resolution LSO PET scanner. 
Imaging was performed in sternal recumbency under general anesthesia 77.10 ± 12.83 
minutes (mean±SD) after animals received an intravenous injection of 93.36 ± 41.75 
MBq 18FLT (mean±SD). Standardized uptake values (SUVs) were calculated based on 
manually drawn regions of interest (ROIs) placed over major parenchymal organs, 
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selected areas of bone marrow, and areas of increased tracer accumulation. Uptake 
was observed primarily within the urinary and biliary systems, bone marrow, and 
intestinal tract. Moderate uptake was variably observed in lymphoid tissues. Tracer 
retention in the brain, lung, myocardium, skeletal muscle, and spleen was generally low 
to mild, although a focal area of increased splenic uptake was observed in one animal. 
Introduction 
Veterinary interest in advanced imaging modalities, including positron emission 
tomography (PET) and combined positron emission tomography/computed tomography 
(PET/CT), is growing as clinicians and researchers gain access to equipment and 
clients increasingly demand access to care for their animals that is similar to that in 
human medicine [1-4]. Most PET and PET/CT studies have utilized 2-deoxy-2-[18F]-
fluoro-D-glucose (18FDG), a radiopharmaceutical analog of glucose whose uptake 
reflects the energy utilization of tissues [5, 6]. The popularity of 18FDG is due in large 
part to its versatility, as many pathological and physiological conditions are 
accompanied by alterations in glucose management [6]. Unfortunately, this also 
underlies one of the major pitfalls of this tracer, particularly in the context of oncology. It 
is not only tumors which accumulate the tracer, but also areas of inflammation and 
various normal tissues which utilize glucose to meet their energy demands [7-11]. As a 
result, alternative tracers must be investigated for applications where 18FDG is either 
inappropriate or inadequate. 
3'-deoxy-3'-[18F]fluorothymidine (18FLT) is a radiopharmaceutical analog of thymidine 
whose uptake and retention is more directly related to the cellular processes of 
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proliferation [12]. Similar to the way in which 18FDG is trapped intracellularly following 
phosphorylation early in the glycolytic pathway, 18FLT is trapped after being 
phosphorylated by thymidine kinase 1 (TK1) as part of the pyrimidine salvage pathway 
of DNA synthesis [13-15]. Although it is not ultimately incorporated into DNA as it lacks 
the necessary 3’ hydroxyl, TK1 activity is tied closely to the cell cycle and uptake of the 
tracer has generally been shown to correlate favorably with traditional measures of DNA 
synthesis [3, 14, 16, 17].  
In recent years, 18FLT has become one of the most prominent of the so-called 
“proliferation markers”, and its utility has been investigated for a broad range of human 
cancers in the diagnosis, staging, and/or measurement of therapeutic response [14, 18]. 
It has also been used as a diagnostic tool to analyze various bone marrow dyscrasias 
and to map normal proliferative marrow [19-24]. Although veterinary usage has been 
more limited to date, clinical investigations have utilized 18FLT-PET in the assessment 
of a variety of canine cancers [2, 25-28]. Whole-body biodistribution of 18FLT has been 
described in the cat [29] and early descriptions of physiologic 18FLT distribution were 
based on dogs; however, comprehensive descriptions of biodistribution are still needed 
to aid image interpretation in this species [3, 12, 30]. The present study describes the 
normal distribution of 18FLT in a small cohort of healthy, adult dogs. 
Methods 
Six healthy, purpose-bred, mixed-breed dogs were obtained through the Laboratory 
Animal Facilities at the University of Tennessee College of Veterinary Medicine. The 
study sample included 2 males (one intact, one castrated) and 4 spayed females. Age 
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ranged from 3 to 6 years (mean = 4.67 yrs) and weight ranged from 15.45 kg to 25.91 
kg (mean = 19.09 kg). All animals were housed throughout the study in Institutional 
Animal Care and Use Committee (IACUC)-approved housing facilities and all 
procedures were conducted in compliance with a University of Tennessee IACUC-
approved research protocol. Dogs were deemed to be healthy based on the results of 
physical examination, recent hematology and clinical chemistry testing, as well as 
routine history as university-maintained research animals. Additionally, no abnormalities 
were observed in any animal upon evaluation of whole-body computed tomography 
(CT) during the study. 
The imaging protocol included general anesthesia for immobilization and positioning. All 
animals were fasted for a minimum of 12 hours prior to placement of an intravenous 
catheter in a peripheral vein and sedation with acepromazine (0.025-0.05 mg/kg) and 
butorphanol (0.2-0.4 mg/kg). At the time of sedation, animals were intravenously 
injected with 93.36 ± 41.75 MBq 18FLT (mean±SD). The initial two study animals were 
administered 146.34 ± 0.26 MBq (mean ± SD) while the dosage was reduced to 66.88 ± 
9.98 MBq (mean±SD) in later animals with no appreciable alteration in imaging 
characteristics. Following a 60-90 minute uptake period during which the animals were 
confined to a small cage, general anesthesia was induced via intravenous bolus of 
propofol (≤4 mg/kg) followed by maintenance with inhaled isoflurane.  
18FLT utilized in this study was produced on-site by the radiochemistry laboratory of the 
Molecular Imaging and Translational Research Program at the University of Tennessee 
Graduate School of Medicine via a flow-based microfluidic chemistry system. The 
63 
 
reaction product was purified by semi-prep high-performance liquid chromatography 
(HPLC) in order to yield >99% radiochemically pure 18FLT for injection. 
PET/CT imaging was performed in ventral recumbency 77.10 ± 12.83 minutes 
(mean±SD) after 18FLT injection using a Biograph mCT scanner (Siemens Medical 
Solutions USA, Inc., Knoxville, TN). This scanner combines a 64-slice helical CT 
scanner with a high resolution LSO PET scanner within a single housing. The unit 
incorporates a 78 cm patient bore with a 50 cm transverse (x,y) field-of-view; the z-axis 
field-of-view covers 21.8 cm. CT and PET imaging were performed sequentially with no 
alteration in subject positioning following an initial topogram defining the area of interest. 
CT data were utilized for attenuation correction during PET reconstruction as well as to 
aid image analysis. CT scans were performed at 120 kV and 150 mAs with Care 
Dose™ using a 0.8 pitch and 0.6 mm acquisition slice width. CT data were later 
reconstructed using 5 mm and 2.5 mm slice thicknesses for image analysis. PET 
imaging required 9 to 11 bed positions in order to encompass the entire body of the 
dogs and immediately followed completion of the CT scan. PET data were acquired for 
3 minutes per bed position with an energy acceptance window of 435-650 keV. PET 
reconstruction was performed using the TrueX algorithm (Siemens Medical Solutions 
USA, Inc., Knoxville, TN) with 3 iterations and 12 subsets resulting in a reconstructed 
pixel size of 4.07 mm x 4.07 mm. Data reconstruction included normalization and 
corrections for dead time, attenuation, scatter, and radioactive decay. 
Regions of interest (ROIs) were manually drawn by a veterinarian trained in molecular 
imaging analysis over sites of observed tracer accumulation, major parenchymal 
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organs, and selected regions of bone marrow (Figure 2.1) using a dedicated analysis 
software package (Inveon Research Workplace v3.0, Siemens Medical Solutions USA, 
Inc., Knoxville, TN). In total, 36 separate ROIs were designated for each animal. Most 
regions were drawn 2-dimensionally using the imaging plane which most easily 
facilitated creation of a representative ROI. Large, homogeneous organs (liver, lung, 
urinary bladder, and epaxial muscle) were assessed via placement of individual 
spherical volumetric ROIs within a representative area of each tissue; care was taken to 
avoid large airways within the pulmonary parenchyma during placement. As urinary 
excretion is known to be a predominate route of 18FLT elimination, renal cortical ROIs 
were drawn with care to exclude the renal pelvis from analysis. Mean and maximum 
standardized uptake values (SUVs) were calculated based on measured body weight 
using dedicated analysis software (Inveon Research Workplace v3.0, Siemens Medical 
Solutions USA, Inc., Knoxville, TN) and are decay-corrected to the time of injection. 
Tracer accumulation data was categorized based on the following definitions: (1) low = 
maximum SUV less than 1; (2) mild = maximum SUV greater than 1 but less than 3; (3) 
moderate = maximum SUV greater than 3 but less than 6; (4) intense = maximum SUV 
of 6 or greater. 
Results 
Biodistribution of 18FLT in the canine is summarized in Table 2.1 and is greatest in the 
urinary and biliary systems, intestinal tract, and bone marrow. Tracer accumulation was 
also variably observed within lymphoid tissues. Whole-body biodistribution images are 
provided in Figure 2.2A and B. 
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The 18FLT signal of greatest intensity was observed within the urinary bladder with 
moderate activity also present within the renal cortices. Static 18FLT signal within the 
hepatic parenchyma was mild at the times of observation in this study; however, intense 
radiopharmaceutical accumulation within the gallbladder was characteristic of all dogs 
evaluated. Variable, multifocal to diffuse intestinal uptake was also observed, although it 
was not possible to discriminate tracer uptake within the intestinal wall from 
accumulation within the lumen. 
Substantial tracer uptake within hematopoietic bone marrow was observed. All dogs in 
this study demonstrated similar distribution of tracer activity within the marrow 
compartment, with intense tracer uptake associated with the vertebral column, sternum, 
and proximal appendicular skeleton. Appendicular 18FLT signal was consistently low to 
mild beyond the proximal aspect of the humerus and femur.  
Lymphoid tissues also variably demonstrated radiopharmaceutical uptake in these 
clinically healthy animals; while uptake was mild on average, measurements in 
individual animals ranged from low to moderate. Although the superficial cervical and 
popliteal lymph nodes were the only lymphoid sites for which ROIs were designated, 
uptake was variably observed in other areas where lymphoid tissues are present (e.g. 
palatine tonsil, retropharyngeal lymph nodes). Neither aspirates nor biopsies were 
evaluated as a part of this study. 
18FLT uptake within the brain, lung, myocardium, skeletal muscle, and spleen was low 
to mild with the exception of a single, focal area of intense uptake (SUV = 16.6) within 




The present study further characterizes the physiologic distribution of 18FLT in the 
canine using PET/CT. Previous investigation in the normal dog utilizing PET without CT 
fusion indicated retention of the tracer in the kidneys and urinary bladder as well as 
selective uptake in tissues with a high proliferative rate like bone marrow. Tracer 
accumulation was also visualized in mandibular lymph nodes, though SUV data was not 
included [12]. Similar to previous findings, we observed intense physiologic uptake of 
18FLT within the urinary system and bone marrow. Accumulation within these tissues is 
a hallmark of 18FLT distribution across multiple species, the former due to elimination 
via the urine, the latter due to the highly proliferative nature of hematopoiesis [12, 29, 
30]. Additionally, we noted increased uptake within the biliary system, intestine, and 
variable uptake within lymphoid tissues. Observed uptake within these regions in the 
normal dog should therefore be considered when evaluating studies in dogs with 
suspected disease. Likewise, tissues which display minimal uptake – the normal brain, 
lung, myocardium, and skeletal muscle – should be kept in mind when considering 
future clinical applications. The unexpected single focus of intense uptake within the 
spleen of one animal is presumed to be caused by extramedullary hematopoiesis; 
unfortunately, samples were not collected to allow confirmation. Splenic uptake was 
otherwise mild in all animals suggesting that uptake in this organ is normally minimal.  
Radiopharmaceutical elimination is a prominent component of the physiologic 
distribution of 18FLT in the domestic dog with the highest uptake observed in the urinary 
and biliary systems. Considerable uptake within the renal cortices and urinary bladder is 
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expected as 18FLT is cleared in large part via the urine, predominately (over 95%) as 
unmetabolized FLT in the canine [12]. Previous in vitro studies of the related compound, 
3’-azido-3’-fluorothymidine (AZT) utilizing cultured hepatocytes support that the canine 
liver is responsible for very little metabolism of a similar substance [31]. This differs from 
humans where robust hepatic glucuronidation occurs, resulting in the presence of 
glucuronide-conjugates of the tracer in blood and urine [32, 33] and marked hepatic 
uptake [12]. The present study confirms mild hepatic tracer retention in the dog as 
compared to the human [12], although intense activity was present in the gallbladder. In 
fact, measurements within the gallbladder were consistently among the highest in this 
study, second only to the urinary bladder. While previous descriptions of the dog do not 
mention tracer accumulation within the gallbladder, an early sagittal image illustrating 
physiologic distribution displays a focal area of uptake in the appropriate location [12]. 
Further investigation evaluating bile and/or feces is needed to discern if the activity 
within the gallbladder is present as the parent compound or a metabolite as well as to 
what degree biliary excretion contributes to the distribution and elimination of the tracer.  
Abundant uptake by the bone marrow is a key feature of physiologic 18FLT distribution. 
In addition to being a site of rapid proliferation, the salvage pathway utilized by 18FLT is 
particularly well-developed in hematopoietic marrow due to the need to recover DNA 
liberated during red blood cell enucleation [33]. The pattern of marrow uptake observed 
in these adult dogs closely mirrors that of adult humans with uptake concentrated in the 
vertebrae, sternum, and ultraproximal appendicular skeleton [34]. Unlike our previous 
observations in the young adult cat [29], discernable uptake was not present beyond the 
proximal aspects of the humeri or femora in any of the dogs evaluated. Conversion of 
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hematopoietic marrow to fat occurs with increasing age [35] and has been previously 
studied in the canine pelvis, femur, and stifle joint using magnetic resonance imaging 
(MRI). These studies suggest that conversion in the distal femur is a variable process, 
but likely occurs between 1 and 3 years of age in the dog [36-38]. Our findings support 
this assertion as conversion to an adult pattern appears to be complete in these 3-6 
year old dogs. 
Intestinal uptake is a frequently observed component of physiologic 18FLT distribution in 
several species [29, 39, 40], though it has not been previously quantified in the dog. 
Moderate to intense intestinal uptake was present in all 6 dogs in this study. Distribution 
was variably multifocal to diffuse so measurements were limited to maximum SUV 
assessed over a large, dorsal plane ROI drawn over a representative portion of the 
small intestine. It is likely that intestinal uptake is the result of proliferating intestinal 
mucosal cells; however, given the intense uptake within the gallbladder, biliary excretion 
may also contribute. 
Variable lymphoid uptake in these clinically healthy animals may confound interpretation 
of clinical studies, particularly when trying to distinguish reactive lymph nodes from 
lymph node metastases. Uptake within superficial cervical and popliteal lymph nodes 
was generally low to mild; however, moderate uptake was observed in two individuals, 
neither of which displayed evidence of disease based on physical examination, 
bloodwork, or anatomical imaging. Although other lymphoid sites were not measured in 
this study, modest uptake was variably present based on visual inspection and uptake 
within mandibular nodes has been previously reported as a component of normal 
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canine biodistribution [12]. Although 18FLT has been shown not to accumulate in 
inflamed tissue since inflammatory cells are recruited from elsewhere [40, 41], 
interpretation of lymph node uptake is more complicated. While several groups have 
evaluated the specificity of 18FLT for detecting lymph node metastases in a variety of 
cancers, results have been mixed [42-47]. Troost et al, who reported very low specificity 
for identifying lymph node metastases in 10 patients with head and neck cancer, 
determined that uptake by non-metastatic reactive lymph nodes occurs in germinal 
centers due to proliferating B-lymphocytes [46].  
Regional uptake measurements in this study were expressed using the SUV, a semi-
quantitative measure which relates uptake within an ROI to the administered 
radiopharmaceutical dose and patient weight. As SUVs are calculated from static 
images, which allow the assessment of multiple bed positions within a single study, they 
are a convenient and popular alternative in the clinical setting. Unfortunately, SUVs are 
also subject to influence by a variety of patient, equipment, and protocol-related 
elements beyond individual and species-specific physiologic factors. Among these are 
body composition, scanner specifications, image reconstruction algorithm, length of 
uptake period, and various aspects of the individual ROI such as size, method of 
placement, and whether average or maximum activity values are utilized [48-52]. SUV 
measurements of normal tissues in the dog are limited in the literature, but mean SUV 
in the vertebral marrow has been reported to be approximately 4.7 [12, 30]. While this 
measurement is somewhat lower than our measurements presented herein, it is difficult 
to compare values due to variability between studies and it is unclear specifically where 
previous measurements were assessed. While comparisons among species must be 
70 
 
approached with caution, it is interesting to note that relative to our previous description 
of feline 18FLT biodistribution [29], which used the same scanner and protocols, canine 
marrow and biliary uptake is much higher, while uptake in the hepatic parenchyma, 
renal cortices, and urinary bladder is lower. Further investigation is required to 
determine the mechanisms responsible for these differences. 
As PET and PET/CT continue to make inroads into veterinary medicine, detailed 
descriptions of normal tracer distribution in veterinary species are needed to support 
interpretation of studies in clinical patients. This study expands upon initial descriptions 
of 18FLT distribution in the dog [12, 30] and provides reference data from healthy, adult 
animals for comparison. Further studies are needed to define the implications of biliary 
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Table 2.1 Mean and maximum standardized uptake values of 18FLT uptake measured 
with positron emission tomography/computed tomography for selected regions in 
healthy, adult dogs (n=6) 











Urinary Bladder 59.65 (30.79) 100.17 (49.75) 
Gallbladder 13.00 (3.75) 29.79 (11.34) 
T5 Vertebral Body 7.08 (2.16) 11.10 (3.44) 
L4 Vertebral Body 7.92 (2.03) 10.88 (3.08) 
Proximal Humerus 5.73 (2.18) 10.66 (2.75) 
Sacrum 6.80 (1.24) 10.22 (2.01) 
C6 Vertebral Body 6.55 (1.12) 9.67 (1.76) 
Body of Ilium 6.42 (1.33) 9.33 (1.99) 
Proximal Femur 4.44 (1.53) 7.20 (2.55) 
Sternum 4.07 (0.90) 6.03 (1.74) 
Intestine — 5.30 (0.84) 
Wing of Ilium 3.27 (1.47) 5.03 (2.15) 
Renal Cortex 2.30 (0.41) 4.83 (1.59) 
Superficial Cervical LN 1.31 (1.03) 1.93 (1.70) 
Popliteal LN 1.28 (0.60) 1.80 (0.88) 
Mid Femur 1.37 (0.38) 1.80 (0.58) 
Liver 1.60 (0.36) 1.78 (0.42) 
Mid Humerus 1.43 (0.42) 1.75 (0.56) 
Spleen 1.07 (0.32) 1.37 (0.43) 
Distal Humerus 1.11 (0.24) 1.31  (0.28) 
Myocardium 1.01 (0.24) 1.20 (0.32) 
Epaxial Muscle 1.03 (0.27) 1.13 (0.28) 
Distal Femur 0.30 (0.18) 0.57 (0.28) 
Brain 0.29 (0.08) 0.41 (0.11) 
Lung 0.28 (0.09) 0.36 (0.13) 
    
  




SUV, standardized uptake value; SD, standard deviation.  
SUVs for all paired structure regions of interest were calculated by summing data for both left 
and right sides. Measurements were made 77.10 ± 12.83 (mean±SD) minutes after injection. All 




Figure 2.1 Fused positron emission tomography/computed tomography (PET/CT) 
images depicting selected regions of interest (ROI) used to measure biodistribution in 
dogs. (A) ROIs outlining the left (purple) and right (teal) renal cortices were drawn to 
exclude the renal pelvises (asterisks) on dorsal plane images. The splenic ROI is 
outlined in blue. (B) ROI outlining the right proximal aspect of the humerus drawn to 
approximate clinical sampling site (red). (C) Transverse plane images were used to 
outline the 5th thoracic vertebral body (pink). (D) Large dorsal plane ROI outlining a 
representative portion of the small intestine (green).  






Figure 2.2 Representative images illustrating 18FLT whole-body biodistribution patterns 
observed in healthy adult dogs at 77.10 ± 12.83 minutes (mean±SD) minutes post-
injection. Dorsal (A) and sagittal (B) plane positron emission tomography maximum 
intensity projections are provided. Each dorsal plane image corresponds to the sagittal 
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Abstract 
3’-deoxy-3’-[18F]fluorothymidine (18FLT) is a radiopharmaceutical tracer used with 
positron emission tomography (PET), often in combination with computed tomography 
(CT), to image DNA synthesis, and thus, cellular proliferation. Characteristic 
accumulation of the tracer within hematopoietic bone marrow provides a noninvasive 
means to assess marrow activity and distribution throughout the living animal.  The 
present study utilizes three-dimensional analysis of 18FLT-PET/CT scans to quantify the 
relative skeletal distribution of active marrow by anatomic site in the dog. Scans were 
performed on six healthy, adult (3 to 6 years of age), mixed-breed dogs using a 
commercially available PET/CT scanner consisting of a 64-slice helical CT scanner 
combined with an integrated whole-body, high-resolution LSO PET scanner. Regions of 
interest (ROIs) encompassing 11 separate skeletal regions (skull, cervical spine, 
thoracic spine, lumbar spine, sacrum, ribs, sternum, scapulae, proximal humeri, ossa 
coxarum, and proximal femora) were manually drawn based on CT images and 
thresholded by standardized uptake value to delineate bone marrow activity. Activity 
within each skeletal region was then divided by the total skeletal activity to derive the 
percent of overall active marrow within an individual site. The majority of active marrow 
was located within the vertebral column. Of the sites traditionally accessed clinically for 
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marrow sampling, the proximal humerus contained the largest percentage, followed by 
the ossa coxarum, proximal femur, and sternum, respectively. This information may be 
used to guide selection of traditional marrow sampling sites as well as inform efforts to 
spare important sites of hematopoiesis in radiation therapy planning.  
Introduction 
Bone marrow is a dynamic organ found throughout the skeleton within the medullary 
cavities of long bones and the interstices of spongy bone. In the neonate, most of the 
marrow is active and functions in the formation of blood cells, known as red or 
hematopoietic marrow. As an animal ages, however, much of the marrow is 
progressively replaced by fat, particularly in the extremities [1]. As a result, active 
marrow is normally restricted to portions of the axial and proximal appendicular skeleton 
of the adult. Since much of the axial hematopoietic marrow is difficult to access 
clinically, most diagnostic sampling in veterinary medicine is limited to a few accessible 
sites within the appendicular portion of the distribution. 
Compared to most tissues, hematopoietic marrow is particularly sensitive to radiation 
toxicity. Doses as low as 2-4 Gy have been shown to be capable of producing 
reductions of both cellularity [2] and proliferation [3].  Fractionated doses beyond 30Gy 
generally produce permanent ablation [4],  but a local fractionated dose of only 18Gy 
was sufficient to produce longstanding cell death in the adjacent vertebral marrow of a 
dog receiving intensity-modulated radiation therapy (IMRT) for a primary lung tumor (the 
lung mass itself received a fractionated total dose of 30Gy as a palliative therapy 
protocol) [5]. Although the ultimate clinical impact of bone marrow suppression also 
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depends on volume, the concurrent use of chemotherapy and/or the potential to expose 
rather large areas of bone marrow to lower radiation doses with techniques like IMRT 
make detailed knowledge of marrow distribution an important consideration in 
radiotherapy planning [6]. 
To date, there are few reports that provide specific information about the overall skeletal 
distribution of canine hematopoietic marrow, and most available data are several 
decades old. Existing canine functional marrow distribution data have been based on 
the uptake of 59Fe and 99mTc-sulfur colloid by erythroid precursors and 
reticuloendothelial cells, respectively [7]. Additionally, local cellularity estimates have 
been provided based on microscopic examinations of samples collected from several 
sites throughout the skeleton of euthanized animals [8]. Unfortunately, both studies 
appear to be based on relatively young animals; as a result, it is not clear whether their 
results accurately reflect marrow distribution in the mature dog.  
Today, positron emission tomography combined with computed tomography (PET/CT) 
offers a state-of-the-art method to image and quantify whole-body bone marrow activity. 
Compared to other modern techniques like magnetic resonance imaging (MRI), which 
provides an anatomical approach to imaging marrow distribution based largely on its 
relative fat and water content [9], PET/CT more directly interrogates marrow function by 
exploiting specific physiologic pathways that mediate the distribution of certain positron-
emitting radiopharmaceuticals. In particular, PET/CT using 3'-deoxy-3'-
[18F]fluorothymidine (18FLT) has gained attention in recent years as a powerful tool to 
analyze marrow proliferation [5, 6, 10-15]. As a substrate for the pyrimidine salvage 
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pathway of DNA synthesis, 18FLT enters proliferating cells and becomes trapped due to 
phosphorylation by thymidine kinase 1 (TK1) [16-18]. Although it is not subsequently 
incorporated into DNA, TK1 expression is tightly regulated to the synthetic phase of the 
cell cycle, and 18FLT retention in various tumors has generally correlated well with 
traditional assessments of cellular proliferation [18-24]. Since the salvage pathway is 
particularly robust in hematopoietic marrow due to the recovery of DNA liberated by red 
blood cell enucleation [25], 18FLT-PET/CT is especially well-suited for assessing the 
distribution of proliferating marrow. 
Using existing whole-body 18FLT-PET/CT scans from normal dogs, the present study 
seeks to analyze uptake within the marrow compartment to quantify the relative 
distribution of active marrow throughout the skeleton by anatomical site. This 
information will provide updated distribution data for the adult dog, and may be used to 
improve bone marrow sparing efforts during radiotherapy planning or to inform clinical 
selection of sampling sites for aspirates and biopsies. 
Methods 
18FLT-PET/CT scans from six adult, University of Tennessee-maintained, research dogs 
were utilized to gather data on proliferative bone marrow distribution. The dogs that 
were imaged ranged in age from 3 to 6 years (mean = 4.67 years), weighed between 
15.45 kg and 25.91 kg (mean = 19.09 kg), and included one intact male, one castrated 
male, and four spayed females. Routine history records as well as results of physical 
examination, hematology, clinical chemistry panels, and whole-body CT imaging were 
evaluated to verify that the animals had no underlying adverse health conditions.  
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Scans were performed in ventral recumbency under general anesthesia 77.10 ± 12.83 
minutes (mean±SD) following intravenous injection of either 146.34 ± 0.26 MBq 18FLT 
(mean ± SD; 2 animals) or 66.88 ± 9.98 MBq 18FLT (mean±SD; 4 animals). The 18FLT 
injected was produced on-site by the radiochemistry laboratory of the Molecular Imaging 
and Translational Research Program at the University of Tennessee Graduate School 
of Medicine and was verified by HPLC to be >99% radiochemically pure. The scans 
were produced on a Biograph mCT (Siemens Medical Solutions USA, Inc., Knoxville, 
TN) which combines a 64-slice helical CT scanner with a high resolution LSO PET 
scanner within a single housing. CT and PET imaging were performed in sequence with 
no alteration in subject positioning. CT scans were performed at 120 kV and 150 mAs 
with Care Dose™ using a 0.8 pitch and 0.6 mm acquisition slice width but were 
reconstructed using 2.5 mm slice thicknesses for image analysis. PET imaging was 
performed over 9-11 bed positions in order to encompass the entire body of the dogs 
and immediately followed completion of the CT scan. Each bed position was imaged 
over 3 minutes with an energy acceptance window of 435-650 keV. PET reconstruction 
utilized CT data for attenuation correction and was performed using the TrueX algorithm 
(Siemens Medical Solutions USA, Inc., Knoxville, TN) with 3 iterations and 12 subsets 
resulting in a reconstructed pixel size of 4.07 mm x 4.07 mm. Data was normalized and 
corrected for dead time, scatter, and radioactive decay. 
Regions of interest (ROIs) encompassing 11 separate skeletal sites (skull, cervical 
spine, thoracic spine, lumbar spine, sacrum, ribs, sternum, scapulae, proximal humeri, 
ossa coxarum, and proximal femora) were defined by a veterinarian trained in molecular 
imaging analysis using dedicated analysis software (Inveon Research Workplace v3.0, 
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Siemens Medical Solutions USA, Inc., Knoxville, TN). For each skeletal region, a 3-
dimensional ROI was initially drawn using CT image data with care taken to precisely 
follow anatomical boundaries in all image planes. Once the ROI was confirmed to 
encompass the entire skeletal region and exclude neighboring skeletal sites, co-
registered PET data were utilized to tailor the ROI based on standardized uptake value 
(SUV). A minimum SUV threshold of 2.0 was employed to limit the ROI to bone marrow 
activity and exclude counts from surrounding tissues (a representative image of 
thresholded vertebral ROIs is depicted in Figure 3.1). Tracer activity was measured 
within each thresholded ROI and divided by total skeletal activity to derive the percent of 
active marrow within each skeletal site. 
Results 
The relative percentage of proliferative bone marrow by anatomical region is organized 
in Table 3.1 and illustrated in Figure 3.2. The measured mean ± standard deviation 
percentage of active marrow by skeletal site was 5.74 ± 1.08 for the scapulae, 10.10 ± 
3.81 for the humeri, 3.98 ± 1.80 for the femora, 6.76 ± 1.03 for the ossa coxarum, 4.08 ± 
0.68 for the sacrum, 19.65 ± 2.27 for the lumbar spine, 32.08 ± 3.72 for the thoracic 
spine, 9.59 ± 2.11 for the cervical spine, 0.22 ± 0.19 for the skull, 2.67 ± 1.00 for the 
sternum, and 5.14 ± 2.10 for the ribs. Percentages listed for bilateral structures are 
summed.  
Appendicular proliferative marrow did not extend beyond the proximal aspects of the 
humeri or femora in any of the scans included in this study. Marrow activity within the 
skull was minimal and concentrated caudally. Vertebral activity, which represented the 
91 
 
majority of active marrow measured, was predominately within vertebral bodies; 
however, some activity extended into several larger vertebral processes. A 3-
dimensional image of skeletal marrow activity is depicted in Figure 3.3. 
Discussion 
The relative skeletal distribution of proliferating marrow determined by 18FLT-PET/CT 
reflects what would be expected in an adult animal, with the bulk of marrow activity 
concentrated along the axis of the trunk and adjacent limb bones. When compared with 
the previous description by Greenberg et al [7], several similarities are observed. 
Notably, the relative distribution based on 18FLT uptake was within approximately 2 
percent of the previous estimates determined by both 59Fe and 99mTC-sulfur colloid for 
the scapulae, humeri, sacrum, skull, and sternum. Further, all three methods indicate 
that around 10 percent of total skeletal marrow activity lies within the proximal aspect of 
the humerus, one of the most commonly and easily accessible marrow sampling sites in 
veterinary species. Relative distribution was somewhat lower in other common sampling 
sites, such as the iliac crest and proximal femur, suggesting that sampling from the 
proximal humerus might be preferable in the dog. Larger differences were observed for 
other sites, with distribution comparatively biased toward the vertebral column and away 
from the ossa coxarum, femora, and ribs of the animals included in the present study. 
The disparity was most conspicuous in the measurements of the ribs and thoracic 




Despite a paucity of information about marrow conversion age with respect to specific 
skeletal sites in the dog, MRI studies suggest that conversion in the distal femur likely 
occurs between 1 and 3 years of age [26-29]. Although age was not reported in the 
Greenberg study [7], marrow activity was described in the distal femora and proximal 
tibiae. It is therefore probable that the animals used were somewhat younger than those 
described herein and may have still been undergoing marrow conversion. All of the 
dogs imaged by 18FLT were greater than 3 years of age and none displayed similar 
uptake near the stifle. While this likely explains the differences in femoral 
measurements, it is unclear the extent to which age-related conversion explains the 
discrepancies between the measurements of the ribs or the ossa coxarum, a tissue that 
generally maintains the presence of red marrow despite advanced age [26, 30]. Further 
studies imaging dogs of progressive ages are needed to define the pattern and timing of 
marrow conversion in the canine. 
Although comparisons between species should be considered with caution, it is 
interesting to compare the present canine percentages with those determined in 
humans using similar technology. A 2011 study by Hayman et al [6] used 18FLT-PET/CT 
scans from 13 human cancer patients to describe relative skeletal distribution of 
hematopoietic marrow in much the same way as presented herein. While general trends 
were similar between our measurements of the dog and those of the human, only the 
mean values for the femoral, scapular, and sternal anatomical sites were within 2 
percent of one another. Our results indicate that the dog has a greater percentage of 
active marrow within the humerus and cervical, thoracic, and lumbar portions of the 
vertebral column, but a relatively smaller percentage within the skull, sacrum, ribs, and 
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ossa coxarum. The ribs and clavicles were grouped in the human data, likely explaining 
some of the difference observed since the canine clavicle is extremely small and was 
therefore not included in our assessments. Interestingly, the difference measured 
between the ossa coxarum of the two species was rather large at approximately 18.5 
percent (6.76 versus 25.3 percent). It is probable that differences in the anatomical 
proportions of the various sites explains much of the variation between the two species.  
This data has several potential limitations. First, the small sample size consisted of only 
six scans, all of which were from mixed breed dogs of moderate age. Consequently, 
analysis was limited to basic descriptive statistics and the ability to examine potential 
factors which may influence bone marrow distribution, such as sex, breed, or life stage, 
was limited. ROIs were drawn to exclude adjacent soft tissues and neighboring skeletal 
sites. As a result, partial volume effects (PVE) may influence activity measurements 
between adjoining sites or within very small ROIs due to spillover of imaged activity and 
averaging within voxels. PVE typically occur whenever an object is less than three times 
the full width at half maximum (FWHM) of the reconstructed image resolution [31]. 
Influence is likely minimal for most skeletal regions described, but evaluations of relative 
distribution in narrow or small regions of uptake, like the ribs or skull, may be 
underestimated due to this effect. 
Despite potential limitations, 18FLT-PET/CT provides a robust, whole-body assessment 
of proliferative activity within the marrow compartment. The relative distribution data 
reported herein provides a modern estimate of marrow activity by skeletal site for the 
adult dog based on cellular proliferation. This information should assist planning, both 
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by radiation oncologists aiming to avoid important sites of proliferative marrow and by 
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Table 3.1 Percentage of canine total bone marrow activity by skeletal site 
Site Dog 1 Dog 2 Dog 3 Dog 4 Dog 5 Dog 6 Mean ± SD 
          
Scapulae 7.2 4.6 4.6 6.4 5.2 6.4 5.7 ± 1.1 
Proximal Humerus 5.5 6.4 12.5 12.2 8.8 15.2 10.1 ± 3.8 
Proximal Femur 1.6 3.2 4.2 5.1 3.1 6.8 4.0 ± 1.8 
Ossa Coxarum 6.6 6.7 7.4 7.5 4.8 7.4 6.8 ± 1.0 
Sacrum 3.5 4.4 5.2 4.2 3.5 3.6 4.1 ± 0.7 
Lumbar Spine 21.1 21.4 16.4 19.0 22.2 17.8 19.7 ± 2.3 
Thoracic Spine 33.2 37.5 26.9 31.8 33.9 29.2 32.1 ± 3.7 
Cervical Spine 11.6 10.5 10.0 5.8 11.0 8.7 9.6 ± 2.1 
Skull 0.2 0.1 0.6 0.0 0.2 0.2 0.2 ± 0.2 
Sternum 4.2 2.0 3.6 1.7 2.5 2.0 2.7 ± 1.0 
Ribs 5.4 3.3 8.5 6.3 4.7 2.7 5.1 ± 2.1 
 













Figure 3.1 Sagittal plane image depicting canine vertebral column regions of interest. 








Figure 3.2 Box plots showing percentage distribution of proliferative bone marrow by 
























The work presented herein documents the normal physiologic distribution of 3’-deoxy-
3’-[18F]fluorothymidine (18FLT) in adult dogs and cats. The quantitative measurements 
included throughout this dissertation may serve as reference values to guide image 
interpretation in future clinical studies using this tracer to evaluate animals with 
suspected disease. Observation of similar tracer distribution characteristics in cats, as 
compared to dogs and humans, validates the first documented use of 18FLT in this 
species. Although additional studies are needed to define the metabolism of 18FLT in 
cats and further define that of dogs, positron emission tomography/computed 
tomography (PET/CT) utilizing 18FLT represents a robust diagnostic tool for noninvasive 
imaging of proliferative tissues in veterinary patients. As such, the details of normal 
canine and feline biodistribution will become increasingly relevant as veterinary access 
to PET and PET/CT continues to grow.  
The use of 18FLT-PET/CT to characterize marrow activity has been well defined in 
human medicine, but this technology has not been used previously for this purpose in 
veterinary species. Existing descriptions of canine marrow distribution appear to have 
been based on younger animals that were likely still undergoing marrow conversion. As 
a result, the present use of 18FLT-PET/CT to evaluate the relative skeletal distribution of 
proliferating marrow in dogs may represent the only comprehensive whole-body 
description of the adult pattern of hematopoietic marrow distribution in this species, 
information that is valuable when selecting diagnostic sampling sites or during 
radiotherapy planning to minimize hematologic toxicity. Further studies utilizing this 
technology to define the age-related progression of marrow conversion throughout the 
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